Moneycontrol PRO
HomeNewsBusinessZydus Cadila's acne drug receives USFDA go-ahead

Zydus Cadila's acne drug receives USFDA go-ahead

The company has got final approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 45 mg, 80 mg, 90 mg, 105 mg and 135 mg, Zydus Cadila said in a BSE filing today.

November 24, 2017 / 10:48 IST
Praveg Communications (India) Ltd.

Praveg Communications (India) Ltd.

Zydus Cadila has received final approval from the US health regulator to market minocycline hydrochloride extended release tablets used to treat acne.

The company has got final approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 45 mg, 80 mg, 90 mg, 105 mg and 135 mg, Zydus Cadila said in a BSE filing today.

It has also received tentative approval from the regulator for the tablets in 55 mg, 65 mg and 115 mg.

The company will produce the drug at its formulations manufacturing facility in Moraiya in Ahmedabad.

Minocycline hydrochloride extended release tablets are indicated to treat only inflammatory lesions of non-modular moderate to severe acne vulgaris in patients of 12 years of age or older.

The company has more than 170 approvals and so far filed over 310 abbreviated new drug applications (ANDAs) since it started filings in 2003-04.

PTI
first published: Nov 24, 2017 10:35 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347